Celgene

Celgene was a global biotechnology company that specialized in the discovery, development, and commercialization of therapies for cancer and inflammatory diseases. Founded as a spin-off from the chemical company Celanese, it grew into a major force in oncology and immunology, known for its innovative pipeline and strategic business development. The company was acquired by Bristol-Myers Squibb in a landmark transaction valued at approximately $74 billion, one of the largest deals in pharmaceutical industry history.

History

The company was established in 1986 in Warren, New Jersey, as a subsidiary of Celanese Corporation, focusing initially on biotechnology research. Under the leadership of John W. Jackson, it began developing thalidomide for new applications, a pivotal move that shifted its trajectory toward oncology. A key event was the 1998 FDA approval of Thalomid for the treatment of erythema nodosum leprosum, marking its first commercial success. The company relocated its headquarters to Summit, New Jersey, and executed a reverse merger with Signal Pharmaceuticals in 2000, gaining a robust drug discovery platform. Throughout the 2000s, under CEOs like John H. Weichert and later Mark J. Alles, it transformed into a top-tier biopharmaceutical firm, culminating in its acquisition by Bristol-Myers Squibb in 2019.

Products and research

The company's portfolio was anchored by several blockbuster therapies. Revlimid (lenalidomide), a derivative of thalidomide, became a global standard of care for multiple myeloma and myelodysplastic syndromes, generating the majority of its revenue. Another key product, Pomalyst (pomalidomide), was approved for relapsed multiple myeloma. In inflammatory diseases, Otezla (apremilast) was a first-in-class oral treatment for psoriasis and psoriatic arthritis. Its research efforts were heavily focused on cancer immunotherapy, epigenetics, and protein homeostasis, with clinical programs investigating CAR T-cell therapy and small molecule inhibitors. The research and development pipeline was strengthened through internal discovery and numerous partnerships with academic institutions like the Dana-Farber Cancer Institute and companies such as Juno Therapeutics.

Acquisitions and collaborations

A key growth strategy involved aggressive business development. A major acquisition was the $7.2 billion purchase of Receptos in 2015, gaining ozanimod, a promising asset for multiple sclerosis. Earlier, it acquired Abraxis BioScience in 2010 for $2.9 billion, adding the chemotherapy drug Abraxane. In the cell therapy space, it partnered with and later fully acquired Juno Therapeutics for approximately $9 billion, gaining access to its CAR T platform. Significant collaborations included a multi-year partnership with Agios Pharmaceuticals to develop cancer metabolism drugs, leading to the approval of Idhifa, and alliances with bluebird bio and Acceleron Pharma. These deals were orchestrated by executives like George Golumbeski and were central to building its therapeutic footprint.

Corporate affairs

The company was headquartered in Summit, New Jersey, and operated globally with thousands of employees. Its corporate leadership included long-time Chairman and former CEO Robert J. Hugin, who later served in the United States Senate, and CEO Mark J. Alles. It was a component of the NASDAQ-100 and S&P 500 indices, reflecting its market prominence. The company maintained an active philanthropic arm, the Celgene Foundation, supporting communities and patient advocacy groups. Its corporate culture emphasized innovation, and it consistently ranked highly on lists such as Science magazine's Top Employers. Following the acquisition by Bristol-Myers Squibb, its operations were integrated into the larger company's oncology and immunology business units.

Controversies

The company faced significant scrutiny, particularly regarding the pricing of its flagship drug, Revlimid, which saw repeated annual price increases drawing criticism from patient advocacy groups and members of the United States Congress. It was also involved in litigation concerning the validity of Revlimid patents, with challenges from generic manufacturers like Natco Pharma. The legacy of thalidomide remained a sensitive issue, managed through a strict risk evaluation and mitigation strategy program supervised by the FDA. In 2017, it settled Foreign Corrupt Practices Act allegations with the SEC, related to activities in Russia and other regions. Additionally, the conduct of CEO Mark J. Alles was questioned during congressional hearings on drug pricing prior to the Bristol-Myers Squibb acquisition.

Category:Biotechnology companies of the United States Category:Pharmaceutical companies established in 1986 Category:Companies based in Union County, New Jersey